Alisertib is known to inhibit AURKA and AURKB at high concentrations (>100nM)15 and has been shown to be safe in children with atypical teratoid rhabdoid tumor,16,17 suggesting amenability for translation into the clinic in a timely manner. Here, AURKB is linked to atypical teratoid rhabdoid tumor.